Identification of novel tumour targets
Research type
Research Study
Full title
Identification and validation of novel tumour targets
IRAS ID
316856
Contact name
Lian Ni Lee
Contact email
Sponsor organisation
Infinitopes Ltd
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
The success of immunomodulatory therapy that function through suppression of immune-inhibitory signals expressed on tumours (Hodi et al., 2010) demonstrates the unique potential of autologous T cells inherent to the patient to recognise and eliminate tumour cells. However, there is a paucity of targetable, tumour-specific CD8 T cell targets. Infinitopes has established a liquid chromatography-mass-spectroscopy (LS-MS/MS) workflow to precisely identify de novo T cell tumour targets from tumour tissue. This will be applied to tumour and adjacent healthy tissue samples obtained from REC or HTA-licensed UK-based research tissue banks to uncover novel tumour targets. These will be tested on white blood cells (peripheral blood lymphocytes, PBMCs) from cancer patients or healthy volunteers obtained from UK-based tissue banks (REC or HTA-licensed) to confirm the identified targets are able to stimulate a T-cell response.
REC name
London - Dulwich Research Ethics Committee
REC reference
22/PR/0916
Date of REC Opinion
30 Aug 2022
REC opinion
Further Information Favourable Opinion